East Sunshine Pharmaceuticals hydrochloric acid Fingomod capsule synth siphon saucy.

Multiple sclerosis (MS), a rare disease, is a serious, lifelong, sexual, disabling central nervous system disease that occurs in young adults.
is expected to have about 30,000 multiple sclerosis patients in China, with a peak age of 20-40 years, or young adulthood.
in China, the disease is listed in the first list of rare diseases.
According to the Multiple Sclerosis Patient Survival Report (2018), the current treatment status of multiple sclerosis (MS) in China is far from foreign countries, there is no effective root treatment for multiple sclerosis, mainly in clinical terms with disease correction treatment (Disease-modifying treatments, DMT).
report shows that only 10% of patients can get corrective treatment in Our country, 86% in Europe and the United States, and the level of treatment in foreign countries is very different.
there are fewer multiple sclerosis drugs currently available in the country, with interferon beta-1a (commodity name: Rebif), tefluorolamine and fengomod.
, Fingomod, a 1-phosphate amol receptor regulator originally known as Novartis (commodity name: Gilenya), was approved by the FDA on September 21, 2010 for the treatment of patients with recurrent multiple sclerosis (MS).
Novartis' 2019 financial results show that Fingord's global sales reached $3.223 billion, down slightly from the previous year (2018: $3.341 billion).

domestic, Novartis Finggomod Capsules was included in the first batch of clinically urgently needed new drugs in 2018, submitted domestic applications for listing in April 2019, and was approved for import on July 12, 2019 for the treatment of recurrent multiple sclerosis (RMS) for patients aged 10 or over, Chinese commodity name: Terinya.
January 6, 2020, Novartis announced that Jeringa had issued its first prescription in China and that the drug had been approved in more than 80 countries worldwide so far, benefiting nearly 300,000 patients.
according to the internet, the price of the drug in The country is 10500 yuan / 28 capsules (14 capsules / plate), excluding the gift of the drug.
Fingomod's U.S. compound patent expires on February 18, 2019, and in December 2019, Dongsun Pharmaceuticals' fengomode capsule scorpion salt water was the first in the U.S. to be available.
Insight database shows that a total of 6 enterprises in the research company, all approved for clinical research, of which capsules are 4 enterprises in the research, namely, Nanjing Warwick (Chengdu Baiyu Pharmaceutical's hydrochloric acid Fingord capsule transferred to Warwick Pharmaceutical), Howson, Shandong Innovative Drug Research and Development Company, Chinese people's Pla Military Medical Academy Toxic Medicine Research Institute.
East Sunshine Pharmaceuticals fengomod capsule is expected to be produced by the U.S.-China common line, has been approved by the FDA for listing into the priority review, thus accelerating the rate of domestic approval, for patients with multiple sclerosis in the country to bring more drug options.
original title: $3.2 billion of heavyweight varieties, East Sunshine Pharmaceuticals "Fengomod Capsule hydrochloric acid" domestic debut.